We have previously demonstrated that arachidonic acid activates extracellular signal-regulated protein kinases (ERKs) group of mitogen-activated protein kinases (MAPKs) in vascular smooth muscle cells (VSMC). To understand the role of arachidonic acid in cellular signaling events, we have now studied its eect on jun N-terminal kinases (JNKs) group of MAPKs in VSMC. Arachidonic acid activated JNK1 in a time-and concentration-dependent manner with maximum eects at 10 min and 50 mM. Induced activation of JNK1 by arachidonic acid is speci®c as other fatty acids such as linoleic and stearic acids had no such eect. Indomethacin and nordihydroguaiaretic acid (NDGA), potent inhibitors of the cyclooxygenase (COX) and the lipoxygenase (LOX)/monooxygenase (MOX) pathways, respectively, had no eect on arachidonic acid activation of JNK1 suggesting that the observed phenomenon is independent of its metabolism through either pathway. However, 12-hydroperoxyeicosatetraenoic acid (12-HpETE), the LOX metabolite of arachidonic acid signi®cantly induced JNK1 activity. Protein kinase C (PKC) depletion by prolonged treatment of VSMC with phorbol 12-myristate 13-acetate (PMA) resulted in partial decrease in the responsiveness of JNK1 to arachidonic acid suggesting a role for both PKCdependent and -independent mechanisms in the activation of JNK1 by this important fatty acid. On the other hand, the responsiveness of JNK1 to 12-HpETE was completely abolished in PKC-depleted cells, suggesting a major role for PKC in 12-HpETE-induced JNK1 activation. IL-1b and TNF-a activated JNK1 in a time-dependent manner with maximum eect at 10 min. Desensitization of JNK1 by arachidonic acid signi®-cantly reduced its responsiveness to both the cytokines. In addition, 4-bromophenacyl bromide (4-BPB), a potent and selective inhibitor of phospholipase A 2 (PLA 2 ), signi®cantly attenuated the cytokine-induced activation of JNK1. Together, these results show that (1) arachidonic acid and its LOX metabolite, 12-HpETE, activate JNK1 in VSMC, (2) PKC-dependent and -independent mechanisms play a role in the activation of JNK1 by arachidonic acid and 12-HpETE, and (3) arachidonic acid mediates, at least partially, the cytokine-induced activation of JNK1.
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Keywords: arachidonic acid; cytokines; growth factors; JNK1; signaling Arachidonic acid is a cis-polyunsaturated essential fatty acid and is a component of membrane phospholipids. It exists at very low levels intracellularly (Exton, 1994; Piomelli, 1993) . Arachidonic acid can be generated by: (1) phospholipase A 2 (PLA 2 ) hydrolysis of phospholipids; (2) phospholipase C (PLC) hydrolysis of phospholipids forming diacylglycerol (DAG) which in turn is hydrolyzed by DAG lipase; and (3) phospholipase D (PLD) hydrolysis of phospholipids generating phosphatidic acid (PA) and subsequent hydrolysis of PA by speci®c lipase or PLA 2 (Exton, 1994; Piomelli, 1993) . PLA 2 , however, appears to be a rate limiting enzyme for generation of free arachidonic acid (Exton, 1994; Piomelli, 1993; Davidson and Dennis, 1990) . Upon generation, arachidonic acid can be reincorporated into membrane phospholipids via its conversion to arachidonylCoA by arachidonyl-CoA synthetase, or can be metabolized to prostaglandins, hydroperoxyeicosatetraenoic acids or epoxides via the COX, the LOX or the cytochrome P450 monooxygenase (MOX) pathways, respectively (Piomelli, 1993) .
Arachidonic acid and its metabolites play an important role in several biological processes including in¯ammation (Asaoka et al., 1993a; Schalkwijk et al., 1992) , vaso-contraction and -relaxation Ma et al., 1993) , migration (Nakao et al., 1982) , homeostasis (Kim and Clapham, 1989) , cell-proliferation/dierentiation (Asaoka et al., 1993b; Butcher et al., 1993) and apoptosis (Jaattela et al., 1995) . In recent years, it was demonstrated that various bioactive molecules such as peptide growth factors, hormones, cytokines and cellular stresses such as oxidant stress induce generation of arachidonic acid in several cell types (Rao et al., 1995; Lin et al., 1992; Peppelenbosch et al., 1992; Schalkwijk et al., 1992; Haliday et al., 1991) . A role for arachidonic acid and its metabolites in growth factor-induced mitogenesis has been demonstrated (Dethlefsen et al., 1994; Glasgow et al., 1992; Fafeur et al., 1991; Sellmayer et al., 1991; Harris et al., 1990; Ralph and Wojcik, 1990) . In addition, arachidonic acid has been shown to be a potent activator of several intracellular signaling kinases such as PKC and ERKs (Hii et al., 1995; Rao et al., 1994a; Kikkawa et al., 1988; McPhail et al., 1984) . ERKs have been shown to be activated by and involved in mitogen-induced growth signaling events (Whitmarsh and Davis, 1996; Karin, 1995) . Although earlier studies showed that JNKs, another subgroup of MAPKs, are preferentially activated by agonists that do not necessarily cause growth and cellular stresses such as u.v. irradiation Kyriakis et al., 1994; Sluss et al., 1994) , recent reports have demonstrated a role for these kinases in the regulation of cell growth (Mitsui et al., 1997; Yang et al., 1997; Rao and Runge, 1996) . To understand the role of arachidonic acid in cell growth and intracellular signaling events, we have studied its eect on JNK1. In the present study, we demonstrate that: (1) arachidonic acid and its LOX metabolite 12-HpETE potently activate JNK1 in growth-arrested VSMC; (2) arachidonic acid activation of JNK1 is independent of its metabolism through the COX or the LOX/MOX pathways; (3) activation of JNK1 by arachidonic acid appears to be mediated by both PKC-dependent and -independent mechanisms, whereas 12-HpETE-induced JNK1 activation appears to be PKC-dependent, and (4) arachidonic acid mediates, at least in part, the cytokine-induced JNK1 activation.
To determine whether arachidonic acid activates JNK1, growth-arrested VSMC were treated with arachidonic acid (50 mM) for various time periods and cell extracts were prepared. Equal amounts of protein from control and treatments were immunoprecipitated with anti-JNK1 antibodies in the presence of protein A-sepharose beads and the JNK1 activity was measured using immunocomplex kinase assay as described previously (Rao and Runge, 1996) . Arachidonic acid induced JNK1 activity in a time-dependent manner with maximum eect (sevenfold) at 10 min and returning to almost basal levels by 30 min (Figure 1 ). In addition, arachidonic acid-induced JNK1 activity was found to be concentration-dependent with threeand tenfold increases at 5 and 50 mM, respectively ( Figure 1 ). In order to ®nd whether activation of JNK1 is speci®c to arachidonic acid or can be activated by other polyunsaturated or saturated fatty acids which are constituents of membrane phospholipids, growtharrested VSMC were treated with arachidonic, linoleic or stearic acid (50 mM) for 10 min and the JNK1 activity was measured. Of the three fatty acids tested, only arachidonic acid signi®cantly induced JNK1 activity (data not shown).
Arachidonic acid can be metabolized via the COX, LOX or MOX pathways generating potential biological mediators such as prostaglandins (PGs), hydroperoxyeicosatetraenoic acids (HpETEs) or epoxides (Exton, 1994; Piomelli, 1993) . Therefore, we wanted to examine whether arachidonic acid metabolism through one of the above pathways is required for its activation of JNK1. To answer this issue, growtharrested VSMC were treated with arachidonic acid (50 mM) in the presence and absence of indomethacin (10 mM) or NDGA (10 mM), potent inhibitors of the COX and LOX/MOX pathways, respectively (Rao et al., 1994a) , for 10 min and the JNK1 activity was determined. We have previously reported that VSMC metabolize arachidonic acid via the COX and LOX pathways into PGE 2 and 15-HpETE, respectively. In addition, we showed that indomethacin and NDGA, at the concentrations used in the present study, inhibit the COX-and LOX-mediated arachidonic acid metabolism in these cells (Rao et al., 1994a) . Interestingly, neither of the inhibitors interfered with arachidonic acid-induced activation of JNK1 ( Figure  2 , upper panel). Consistent with this observation, treatment of growth-arrested VSMC with 1 mM PGE 2 or 5-, and 15-HpETEs did not result in signi®cant JNK1 activation (Figure 2 , middle panel). However, 12-HpETE, the 12-LOX metabolite of arachidonic acid, considerably activated JNK1 at 1 mM. Hence, we studied the dose response eect of this eicosanoid on JNK1 activation. Surprisingly, 12-HpETE caused JNK1 activation in a dose-dependent manner with maximal eect at 100 nM (Figure 2, bottom panel) . The greater eectiveness of this eicosanoid at lower concentrations compared to higher concentrations was also reported in other systems in regard to its angiogenic activity (Schwartzman et al., 1994) . Together, these ®ndings suggest that arachidonic acid and 12-HpETE, when added exogenously, independently activate JNK1.
Earlier studies have demonstrated that cis-polyunsaturated fatty acids and their metabolites such as HETEs activate PKC isozymes of conventional type (a, b and g isozymes) in several cell types (Liu et al., 1995; Kikkawa et al., 1988; Hansson et al., 1986; McPhail et al., 1984) . To understand the mechanism by which arachidonic acid and 12-HpETE induce JNK1 activity, the role of PKC on arachidonic acid and 12-HpETE activation of JNK1 was tested. PKC was depleted by treatment of VSMC with PMA (1 mM) for 16 h and the JNK1 activity was measured in response to arachidonic acid and 12-HpETE. Several laboratories including ours have previously shown that treatment with PMA for 412 h is sucient to signi®cantly down-regulate the PMA responsive PKC isozymes and PKC-dependent early response events in this cell type (Lu et al., 1996; Rao et al., 1993 Rao et al., , 1994a . PKC down regulation resulted in 36% decrease in the activation of JNK1 by arachidonic acid (Figure 3) , a Figure 1 Arachidonic acid activates JNK1 in a time-and dosedependent manner: Isolation and culturing of rat VSMC were as described by Rao et al. (1994a) . Growth-arrested VSMC were treated with 50 mM arachidonic acid for the indicated times or with the indicated concentrations for 10 min and the JNK1 activity was measured by an immunocomplex kinase assay as described previously (Rao and Runge, 1996) using GST-c-Jun (1 ± 79) as a substrate. These results were reproduced in three independent experiments ®nding which suggests that arachidonic acid activates JNK1 in both PKC-dependent and -independent mechanisms. On the other hand, the responsiveness of JNK1 to 12-HpETE was 80% decreased in PKCdepleted cells suggesting that PKC plays a major role in 12-HpETE-induced JNK1 activation. PMA also activated JNK1 in a time-dependent manner with a maximum eect at 10 min (data not shown) and this response, as expected, was found to be sensitive to PKC-down regulation (Figure 3) .
A large number of studies have shown that cytokines and growth factors induce the release of arachidonic acid in several cell types (Rao et al., 1994b; Schalkwijk et al., 1992; Lin et al., 1992; Peppelenbosch et al., 1992; Haliday et al., 1991) . Because arachidonic acid activated JNK1 acutely, we wanted to test whether this fatty acid plays a role in cytokine activation of JNK1. To address this issue, we ®rst studied the time course of IL-1b and TNF-a on the activation of JNK1 in growth-arrested VSMC. Both IL-1b (50 ng/ml) and TNF-a (20 ng/ml) caused a time-dependent activation of JNK1 with a maximum eect at 10 min (Figure 4a , upper panel). To investigate whether arachidonic acid plays a role in cytokine-induced activation of JNK1, growth-arrested VSMC were treated with arachidonic acid for 30 min prior to challenging the cells with arachidonic acid, IL-1b or TNF-a for 10 min. Arachidonic acid-induced desensitization of JNK1 signi®cantly reduced its responsiveness to all three agonists (Figure 4a, lower panel) . Earlier studies have reported that cytokines induce arachidonic acid release in a PLA 2 -dependent manner (Lin et al., 1992; Peppelenbosch et al., 1992; Schalkwijk et al., 1992) . To determine the possible role of PLA 2 in cytokineinduced JNK1 activation, we studied the eect of 4-BPB, a potent and selective inhibitor of PLA 2 (Sakata et al., 1987) , on IL-1b and TNFa-induced JNK1 activation. As shown in Figure 4b , 4-BPB (5 mM) signi®cantly inhibited both IL-1b (50 ng/ml) and TNFa (20 ng/ml)-induced JNK1 activation. To examine whether PKC plays a role in cytokine-induced JNK1 activation, growth-arrested and PKC-depleted VSMC were treated with either IL-1b or TNF-a for 10 min and JNK1 activity was measured. PKC-down regulation did not decrease the responsiveness of JNK1 to either cytokine (data not shown).
The important ®ndings of the present study are that: (1) arachidonic acid and 12-HpETE activate JNK1 in growth-arrested VSMC; (2) arachidonic acid activation of JNK1 is independent of its metabolism through the COX or the LOX/MOX pathways; (3) both PKCdependent and -independent mechanisms account for arachidonic acid-induced activation of JNK1, and (4) arachidonic acid mediates, at least in part, the cytokine-induced activation of JNK1. Arachidonic acid activation of JNK1 and its role in cyokineinduced JNK1 activation have been reported in other cell types by two other groups (Cui and Douglas, 1997; Rizzo and Carlo-Stella, 1996) . Previously, we and others have reported that arachidonic acid activates ERKs in VSMC and in epithelial cells, respectively (Hii et al., 1995; Rao et al., 1994a) . In addition, we observed that arachidonic acid-induced ERKs activation is, to a major extent, PKC-dependent. ERKs are a group of serine/threonine kinases which are activated in response to a variety of mitogenic stimuli (Whitmarsh and Davis, 1996; Karin, 1995) . Activation of ERKs requires phosphorylation on both tyrosine Figure 3 Role of PKC in arachidonic acid and 12-HpETE activation of JNK1: Growth-arrested and PKC-depleted VSMC were treated with 50 mM arachidonic acid or 100 nM 12-HpETE for 10 min and the JNK1 activity was determined. These results were reproduced in three independent experiments and threonine residues which is catalyzed by dual speci®city enzymes known as mitogen-activated protein kinase kinase 1 and 2 (MEK 1/2) (Whitmarsh and Davis, 1996; Karin, 1995) . MEK 1/2 are activated by an upstream serine/threonine kinase known as Raf1, which in turn is activated by GTP binding protein Ras (Whitmarsh and Davis, 1996; Karin, 1995) . In parallel to this pathway, another kinase cascade leading to activation of JNK/SAPK (stress-activated protein kinases) has been discovered (Derijard et al., , 1995 Lin et al., 1995; Kyriakis et al., 1994; Sanchez et al., 1994; Sluss et al., 1994; Yan et al., 1994) . Among the six upstream MKKs identi®ed till date, MKK4 (SEK1) has been shown to exhibit high substrate anity towards JNK/SAPK (Derijard et al., 1995; Lin et al., 1995) . Likewise, several upstream serine/threonine kinases including mixed lineage kinase 3 (MLK3) and MEKK1 that can phosphorylate and activate MKK4 have been identi®ed (Rana et al., 1996; Yan et al., 1994) . In addition, several small GTP binding proteins such as Rac and Cdc42 Coso et al., 1995; Minden et al., 1995) and protein tyrosine kinases such as Pyk2 and Vav Tokiwa et al., 1996) have been reported to stimulate JNK/SAPK pathway and lie upstream to the MEKK1. In fact, earlier studies have demonstrated that arachidonic acid and its LOX metabolites, HETEs, activate these GTP binding proteins by inhibiting the activity of their respective GTPase activating proteins (GAPs) (Han et al., 1991; Yu et al., 1990; Tsai et al., 1988 Tsai et al., , 1989 . Because arachidonic acid and its LOX metabolites possess the ability to activate GTP-binding proteins such as Rac, it is likely that these proteins play a role in the activation of JNK1 by these lipid molecules. As arachidonic acid-induced activation of JNK1 requires PKC only to a small extent, and the majority of it appeared to be PKC-independent, it is possible that arachidonic acid activates JNK1 via dierent mechanisms: by directly activating the GTPbinding proteins such as Rac or by activation of MEKK1 via PKC. It is also possible that arachidonic acid activation of JNK1 is mediated by more than one signal transduction pathway. This can be further supported by the recent ®ndings that maximal activation of ERKs by growth factors requires more than one signal transduction mechanism (Knoepp et al., 1996) .
A role for arachidonic acid in cytokine-induced JNK1 activation is strongly suggested by the following ®ndings: (1) Desensitization of JNK1 activation by arachidonic acid reduced the responsiveness of JNK1 to IL-1b and TNF-a; and (2) 4-BPB, a potent and selective inhibitor of PLA 2 , reduced the JNK1 activation induced by both the cytokines. The latter ®nding also suggests a role for PLA 2 in cytokineinduced activation of JNK1. This can be further supported by the fact that arachidonyltri¯uromethyl ketone (AACOCF 3 ), a potent inhibitor of cytosolic PLA 2 (cPLA 2 ), also signi®cantly blocked the cytokine activation of JNK1 (Madamanchi and Rao, unpublished results). The lack of the eect of PKC-down regulation on IL-1b and TNF-a-induced JNK1 activation is consistent with the observation that the majority of arachidonic acid-induced activation of JNK1 is PKC-independent. Both receptor tyrosine kinase and G protein-coupled receptor agonists have been reported to induce the release of arachidonic acid in many cell types (Rao et al., 1994b; Lin et al., 1992; Fafeur et al., 1991) . In addition, receptor tyrosine kinase agonists such as epidermal growth factor (EGF) and G protein-coupled receptor agonists such as thrombin and angiotensin II have been reported to activate JNK1 in VSMC as well as in other cell types (Rao and Runge, 1996; Zohn et al., 1995; . It will be interesting to examine whether arachidonic acid plays a role in these agonist-induced JNK1 activation. However, arachidonic acid release in Growth-arrested VSMC were treated with IL-1b (50 ng/ml) or TNF-a (20 ng/ml) for the indicated times and JNK1 activity was determined. Lower panel: Desensitization of JNK1 by arachidonic acid reduces its responsiveness to cytokines. Cells that were treated with arachidonic acid (50 mM) for 30 min were challenged with arachidonic acid (50 mM), IL-1b (50 ng/ml), or TNF-a (20 ng/ml) for 10 min and the JNK1 activity was determined. (b) 4-BPB, a potent and selective inhibitor of PLA 2 , blocks cytokine-induced JNK1 activation: Growth-arrested VSMC were treated with and without IL-1b (50 ng/ml) or TNF-a (20 ng/ml) in the presence and absence of 4-BPB (5 mM) for 10 min and JNK1 activity was determined response to various agonists may be mediated by dierent mechanisms and coupling such events to various down stream signaling kinase cascades may confer speci®city to arachidonic acid in the transmission of signals induced by those agonists. Future studies should delineate the role of arachidonic acid in growth factor-induced activation of the JNK/SAPK pathway which leads to modulation of nuclear events and thereby growth.
